BCL2L1 and B-cell chronic lymphocytic leukemia: For example, in patients with chronic lymphocytic leukemia (CLL), low MCL1 expression and high BIM:MCL-1 or BIM:BCL-2 ratios correlate with increased response to navitoclax (BCL-2/BCL-XL/BCL-W inhibitor) [95].